Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
- October 24, 2025 - Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-onset, short-duration GLP-1 therapy targeting both weight management and acute IBS pain, today announced that Chief Executive Officer Enda Kenny, PhD will present data from its recent clinical trial in weight management at #ObesityWeek2025 (sponsored by The Obesity Society) on Tuesday, November 4, 2025 at 7:30 p.m
What is the usage regimen of AOD9604 AOD9604 is a peptide that mimics the lipolytic properties of growth hormone without the diabetogenic side effects
It covers the provider's skill, time, preparation, and supervision involved in delivering the injection
As fat tissue grows and more NNMT is produced, higher amounts of hormones and pro-inflammatory signals are produced that are responsible for weight gain and other chronic diseases such as type 2 diabetes and cardiovascular disease. NNMT is responsible for converting nicotinamide (NA) into 1-methylnicotinamide (1-MNA), which takes it out of the NAD salvage pathway (see the diagram below)
Some individuals experience periods where progress slows despite continued adherence to diet and exercise
An identical copy of the COA is mirrored in the on-page public library, retrievable by lot number for compliance or audit review at any later point.
US$ 25.39
US$ 25.50
US$ 22.19
US$ 27.52
US$ 29.19
US$ 24.28
US$ 27.09
